Clinical Trial Update: Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluates nab-paclitaxel (ABI-007) in combination with gemcitabine or with split-dose leucovorin and 5-fluorouracil (sLV5FU2) as first-line ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ABI-007 (nab-paclitaxel) (nab-paclitaxel)
• Gemcitabine (Gemcitabine)
• sLV5FU2 (split-dose leucovorin + 5-fluorouracil) (split-dose leucovorin + 5-fluorouracil)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: UNKNOWN